The video highlights the distinctions between pharmacologic and physiologic effects of certain hormones and explores the impacts of GLP1 agonists, a class of pharmaceuticals used for weight loss and diabetes treatment. It explains how GLP1 drugs achieve much higher concentrations than naturally occurring hormones in the body, which can have both approved and unexpected benefits, such as reducing heart disease risks and potential anti-inflammatory effects. Despite concerns about the high doses, long-term trial data suggest these drugs are generally safe and have various health benefits, some of which occur independently of weight loss.

This discussion is particularly relevant as it explains the significance of large cardiac outcome trials required by the FDA, which have demonstrated additional health benefits of drugs like Semaglutide beyond weight loss. The video also delves into the commercial aspects of drug development, including how pharmaceutical companies extend patents and develop combinations of GLP1 agonists with other compounds to enhance their effectiveness. The trends suggest a shift in pharmaceutical strategies towards discovering multiple uses for existing drugs, prolonging their market dominance.

Main takeaways from the video:

Please remember to turn on the CC button to view the subtitles.

Key Vocabularies and Common Phrases:

1. physiologic [ˌfɪziəˈlɒdʒɪk] - (adjective) - Relating to the normal functions and activities of living organisms and their parts. - Synonyms: (biological, natural, functional)

So physiological is what the hormone naturally does in your body and what can be modulated by natural things like eating a different food.

2. pharmacologic [ˌfɑːrməkəˈlɒdʒɪk] - (adjective) - Relating to drugs or the science of drugs, including their preparation, properties, uses, and effects. - Synonyms: (pharmaceutical, medicinal, therapeutic)

These GLP1 agonists are really a pharmacologic effect effect that only happens with drugs.

3. agonist [ˈæɡənɪst] - (noun) - A substance that initiates a physiological response when combined with a receptor. - Synonyms: (activator, stimulator, promoter)

These GLP1 agonists are really a pharmacologic effect effect that only happens with drugs.

4. cardiac [ˈkɑːrdiˌæk] - (adjective) - Relating to the heart. - Synonyms: (heart-related, cardiovascular, coronary)

And for cardiac reasons, but let's really surprising was a lot of that seemed to happen before the people even lose weight, lost weight.

5. mortality [mɔːrˈtælɪti] - (noun) - The state of being subject to death; death rate. - Synonyms: (fatality, death, loss of life)

...reduced the rate of heart attacks, strokes, all cause mortality according to cardiac, for cardiac reasons.

6. incretin ['ɪŋkrɪtɪn] - (noun) - A group of metabolic hormones that stimulate a decrease in blood glucose levels. - Synonyms: (glucose-lowering hormones, metabolic hormones)

This other incretin that we talked about, GYP, GIP.

7. agonism [ˈæɡənɪzəm] - (noun) - The action of an agonist, especially in drug or hormone activity, producing a particular effect. - Synonyms: (activation, stimulation, engagement)

It seems like having that GYP agonism actually acts as an anti nausea effect.

8. neurons [ˈnʊrɒnz] - (noun) - Basic working unit of the brain, a specialized cell designed to transmit information to other nerve cells, muscle, or gland cells. - Synonyms: (nerve cells, brain cells, synapses)

There are GYP receptor neurons in the area post treatment, this nausea center.

9. bariatric [ˌbɛəriˈætrɪk] - (adjective) - Relating to the treatment of obesity. - Synonyms: (weight-loss related, anti-obesity, slimming)

...you're talking about basically bariatric surgery, which is currently the best thing we have.

10. obesity [oʊˈbiːsɪti] - (noun) - The condition of being significantly overweight, increased risk of health problems. - Synonyms: (overweight, corpulence, stoutness)

So there's this other drug on the market that we haven't talked about, but Tirzepatide, which is known as Mounjaro for diabetes, Zep, bound for obesity, which is even better, really in almost every respect a better drug than Ozempic

Ozempic, Mounjaro & GPL-1 Agonists for Weight Loss - Dr. Zachary Knight & Dr. Andrew Huberman

I mean, I think it's important sometimes to distinguish between pharmacologic and physiologic effects. So physiologic is what the hormone naturally does in your body and what can be modulated by natural things like eating a different food. And you might get a two fold change in your GLP1 by eating a different food, you know, one food versus the other. But as we know from those DPP4 inhibitors, it's not going to really change your appetite because the drugs increase at threefold. These GLP1 agonists are really a pharmacologic effect effect that only happens with drugs. So you get 1,000 to 10,000 fold higher concentrations of these drugs in your blood than the natural hormone. And so it's just there's no diet that's ever going to give you that and there's no precedent for it either.

So should we be at all concerned about that? I mean they run clinical trials and address safety, but when you're talking about a thousand fold increase in a essentially a peptide hormone, if we were talking about different peptide hormone, pick one, oxytocin or estrogen, testosterone, they're not really. Broadly speaking, most people would be concerned about thousand fold dosing of something like that. And obviously there are clinical indications where that's important. However, my observation of the ever expanding literature on GLP1 agonists is that there seems to be improvements in reduction in alcohol consumption.

And by the way, why would increasing GLP1 reduce craving for alcohol? It seems like there's an ever expanding list of things that GLP1 agonism is good for. But we are talking about, I would say supra physiological levels when one takes it. And again, I'm not against it, nor for it, I'm just paying attention to the literature. So I would say that that's absolutely right. When you're increasing the level of hormone a thousand fold, you need to be careful and see what's happening. But at the end it's an empirical question, what does it actually do to a person? And it can only be answered through experiments.

And I think the nice thing about these GLP1 drugs that a lot of people don't realize is they've been around approved since 2005, the earliest ones, and even something like Ozempic, which maybe only entered the public consciousness in the last year or two, it's been around for 7ish years I think, and big clinical trials with these drugs and the evidence so far is that they seem to be incredibly safe and as you said, not Just incredibly safe. But they seem to have all these unexpected health benefits that seem to be in some cases even unrelated to weight loss. And so because of the reasons you mentioned, one of the things the FDA requires from these pharmaceutical companies for diabetes drugs is these large cardiac outcome trials.

So basically where you measure stroke and where you measure heart attacks and death from any cardiac cause, big trials like 20,000 people, four years cost like a billion dollars to run. And the data from the Semaglutide, the Ozempic trial came out last year and as expected, reduced the rate of heart attacks, strokes, all cause mortality according to cardiac, for cardiac reasons. But what's really surprising was a lot of that seemed to happen before the people even lose weight, lost weight. So there was already a difference between the placebo group and the semaglutide group before the people on the drug had lost a significant amount of weight. And there was no correlation between the amount of weight they lost and how well they were protected from heart disease.

And that's led many people to think that some of these effects actually could be due to other things the GLP1s are doing that we didn't expect. And so one thing is there's an idea emerging that they are anti inflammatory. These brain regions, the area postrema and the nts, are also really important for this reflex, known as the inflammatory reflex that basically acts, starts with the vagus nerve, goes to these brain regions in the brain stem and then goes back down to the body to basically suppress to prevent out of control inflammation. It's thought that these drugs perhaps have an anti inflammatory effect that explains some of that.

Sounds like the patent on these drugs just got extended by another hundred years. That's a biopharma pharma joke. I mean, just to put context on it, drugs can be patented and sold as a commercial version and not as generic versions until the patent runs out. Unless companies are able to find another approved clinical use, in which case it can be remarketed only as a brand name, not generic version. So a lot of companies, once they do the safety testing and all, given everything they put into the R and D, into the research and development, there's a very big incentive to not necessarily finding new drugs, but finding new uses for the same drugs and not allowing generic versions into the picture.

And that's why it's likely to be based on these, what sounds like additional uses of Ozempic related compounds a long time before there's generic Ozempic available. It will be a while. I don't know. The Exact status of the patents, but I'm guessing it's going to be a while before there are generic versions. But there's a lot of competition coming. So every major pharmaceutical company, or almost every major pharmaceutical company now has a GLP1 program. And some of them are really exciting actually.

So, I mean the general trend in this area is what people call GLP1 plus, which means you take the GLP1 agonist, which is already giving you 15% weight loss or so, and then you add additional things to that to give it additional properties. So one compound is from Eli Lilly, which makes this other. So there's this other drug on the market that we haven't talked about, but Tirzepatide, which is known as Mounjaro for diabetes, Zep, bound for obesity, which is even better, really in almost every respect a better drug than Ozempic. So people lose more weight. So it's about 21% weight loss at a year, fewer side effects, at least at comparable doses.

That seems to be because this other drug, tirzepatide, it has two targets, not one. So whereas Ozempic is just GLP1 receptor agonist, tirzepatide is a dual agonist of GLP1 and this other incretin that we talked about, GYP GIP. And it seems like having that GYP agonism actually acts as an anti nausea effect that sort of counteracts some of the nausea caused by the GLP1. And in the area post treatment, there are GYP receptor neurons in the area post treatment, this nausea center, it allows you to crank up the dose of the GLP1 agonism even further while you're suppressing the nausea and just get even more weight loss.

So now talking about the future, things that aren't available yet, but will be in the next couple of years. So Eli Lilly, the company that makes this drug, tirzepatidemunjaro, they have a triple agonist that's in phase three clinical trials now. So this is now three hormones in one. It's the GLP one which all these drugs have, the gyp, which is the anti nausea component, and then glucagon itself. And so these three hormones all combine in one pillar. And what the glucagon does is it increases energy expenditure.

And this is a well known effect of glucagon. And so you're basically eating less, your nausea isn't as bad, and now you're just burning more calories at baseline. And the results from this drug are incredible. So Basically there's been one phase two trial published and people lost 25% of their body weight at the end of the, I think it was 48 week period and they were still losing weight. So we don't know where the end point, we don't know what the maximum is. So there are bigger, longer trials going on now to figure that out. But, but at that point when you get beyond 25% body weight, you're talking about basically bariatric surgery, which is currently the best thing we have.

These surgeries people do to stomach staples, removing a portion of the stomach, removing a portion of the gut. So really it's a pharmacologic version of bariatric surgery. The other one that I think is really exciting, there's this compound from Amgen right now. It's just a code, it's like AMG133, but it's like Tirzepatide in the sense that it targets both GLP1 and GYP. So it's a dual targeted. But unlike Tirzepatide, which activates the GYP receptor, this Amgen compound inhibits it.

And for reasons that people don't understand, either activating or inhibiting this receptor causes you to lose weight. So still a mystery, but a lot of debate about what's going on there. But the way this Amgen compound activates the GYP receptor or inhibits the GYP receptor rather is that it's an antibody. So all these other things were peptides, but this is a much bigger sexual protein. This is an antibody. And because it's an antibody, it has a much longer lifetime even than something like semaglutide, which is seven days, so it lasts like a month in the blood or something.

And so you can give people monthly injections of this and they lose dramatic amounts of weight. And then at least in this initial trial, at the end of this they stopped and people maintained the weight loss for six months. That's impressive. Potentially because of the long lasting effects of this antibody or potentially because of other things that we don't understand. And those are just two, there's all sorts of other crazy things happening. So really I think it's just created this explosion of interest in pharma. Basically it's one of these things, once you see that something can be done, all of a sudden that changes everyone's perspective.

And so now obesity drug discovery has gone from something that 10 years ago everyone wanted to stay away from because there were so many nightmare stories about drugs that turned out to be not safe. Till now everybody's sort of all in on this. Yeah, I remember in college the fen phen debacle where a diet drug was released and people had cardiac issues started dying so it was pulled from market and then it was essentially a quiet field for a long time.

Pharmacology, Medicine, Health, Technology, Science, Innovation, Huberman Lab Clips